Search details
1.
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.
Ann Hematol
; 102(1): 107-115, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36369497
2.
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Eur J Haematol
; 109(2): 162-165, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35502609
3.
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 2021 08 19.
Article
in English
| MEDLINE | ID: mdl-34407608
4.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 106(9): 2417-2426, 2021 09 01.
Article
in English
| MEDLINE | ID: mdl-34196165
5.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol
; 21(7): 978-988, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32511983
6.
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Hematol Oncol
; 36(1): 110-115, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-29083050
7.
A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.
Br J Haematol
; 191(5): e103-e106, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32862455
8.
Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.
Am J Hematol
; 94(2): E50-E53, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30474171
9.
COVID-19 in 96 Patients With Hematologic Disease: The First Single-center Experience From the Czech Republic.
Clin Lymphoma Myeloma Leuk
; 21(9): 606-612, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34083176
10.
Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.
Cancers (Basel)
; 12(8)2020 Jul 31.
Article
in English
| MEDLINE | ID: mdl-32751805
11.
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Blood Adv
; 4(17): 4091-4101, 2020 09 08.
Article
in English
| MEDLINE | ID: mdl-32877524
12.
Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry.
Leuk Lymphoma
; 60(3): 748-755, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30188225
13.
TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 18(11): 762-768, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30146365
14.
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study.
Leuk Lymphoma
; 63(2): 468-472, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34779360
Results
1 -
14
de 14
1
Next >
>>